Astrazeneca has revealed a jump in revenue from cancer drugs amid rumours its boos is eyeing a listing across the pond. Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology and BioPharmaceuticals, the company told markets this morning…
Read More
About The Author
